Upregulation of SPINK2 in acute myeloid leukemia.

IF 1.1 Q4 MEDICAL LABORATORY TECHNOLOGY

Advances in laboratory medicine Pub Date : 2023-04-01 DOI:10.1515/almed-2022-0047

Sümbül Gezer, Zeliha Emrence, Tuğrul Elverdi, Muhlis Cem Ar, Burcu Salman Yaylaz, Ferda Paçal, Ayşegül Ünüvar, Melda Sarıman, Ahmet Emre Eşkazan, Serap Karaman, Ayşe Salihoğlu, Zeynep Karakaş, Neslihan Abacı, Sema Sırma-Ekmekci

{"title":"Upregulation of SPINK2 in acute myeloid leukemia.","authors":"Sümbül Gezer, Zeliha Emrence, Tuğrul Elverdi, Muhlis Cem Ar, Burcu Salman Yaylaz, Ferda Paçal, Ayşegül Ünüvar, Melda Sarıman, Ahmet Emre Eşkazan, Serap Karaman, Ayşe Salihoğlu, Zeynep Karakaş, Neslihan Abacı, Sema Sırma-Ekmekci","doi":"10.1515/almed-2022-0047","DOIUrl":null,"url":null,"abstract":"Objectives: Acute myeloid leukemia (AML) is a highly heterogeneous disease. Although patients can be classified into risk groups based on their genetic changes, the prognosis of disease within these categories varies widely. This situation raises the need to search for new molecular markers related to AML. Serine peptidase inhibitor Kazal type 2 (SPINK2) has recently been reported to be upregulated in AML and associated with poor outcomes by meta-analysis and in a limited number of AML patients.Methods: We analyzed SPINK2 mRNA expression in 62 patients (45 adult and 17 pediatric) with AML and 11 cell lines using quantitative Real-Time PCR (qRT-PCR). SPINK2 protein level was determined using ELISA in cell lines.Results: We found that the expression of SPINK2 mRNA and protein levels in AML cell lines (HL60 and NB4) have increased compared to other cell lines (K562, Jurkat and NALM6, MCF7, HeLa, HUVEC, hFOB, 293T, U87). SPINK2 mRNA expression was upregulated in patients with AML compared to controls (p=0.004) and significantly lower in t(8;21)-positive patients compared to negative patients (p=0.0006).Conclusions: Our results suggest that SPINK2 serves an important role in AML development. Further studies are needed to evaluate SPINK2 expression in AML patients with t(8.21) and investigate to clarify its prognostic value in various subgroups of AML.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"92-104"},"PeriodicalIF":1.1000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197194/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/almed-2022-0047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Acute myeloid leukemia (AML) is a highly heterogeneous disease. Although patients can be classified into risk groups based on their genetic changes, the prognosis of disease within these categories varies widely. This situation raises the need to search for new molecular markers related to AML. Serine peptidase inhibitor Kazal type 2 (SPINK2) has recently been reported to be upregulated in AML and associated with poor outcomes by meta-analysis and in a limited number of AML patients.

Methods: We analyzed SPINK2 mRNA expression in 62 patients (45 adult and 17 pediatric) with AML and 11 cell lines using quantitative Real-Time PCR (qRT-PCR). SPINK2 protein level was determined using ELISA in cell lines.

Results: We found that the expression of SPINK2 mRNA and protein levels in AML cell lines (HL60 and NB4) have increased compared to other cell lines (K562, Jurkat and NALM6, MCF7, HeLa, HUVEC, hFOB, 293T, U87). SPINK2 mRNA expression was upregulated in patients with AML compared to controls (p=0.004) and significantly lower in t(8;21)-positive patients compared to negative patients (p=0.0006).

Conclusions: Our results suggest that SPINK2 serves an important role in AML development. Further studies are needed to evaluate SPINK2 expression in AML patients with t(8.21) and investigate to clarify its prognostic value in various subgroups of AML.

Abstract Image

查看原文本刊更多论文

SPINK2在急性髓性白血病中的表达上调。

目的:急性髓性白血病(AML)是一种高度异质性的疾病。尽管可以根据患者的遗传变化将其分为危险组，但在这些类别中，疾病的预后差异很大。这种情况提出了寻找与AML相关的新分子标记的需要。丝氨酸肽酶抑制剂Kazal 2型(SPINK2)最近被报道在AML中上调，并与有限数量的AML患者的不良预后相关。方法:采用实时荧光定量PCR (qRT-PCR)分析62例AML患者(45例成人，17例儿童)和11个细胞系的SPINK2 mRNA表达。ELISA法检测细胞中SPINK2蛋白水平。结果:我们发现，与其他细胞系(K562、Jurkat和NALM6、MCF7、HeLa、HUVEC、hFOB、293T、U87)相比，AML细胞系(HL60和NB4)中SPINK2 mRNA的表达和蛋白水平均有所升高。与对照组相比，AML患者的SPINK2 mRNA表达上调(p=0.004)， t(8;21)阳性患者的SPINK2 mRNA表达明显低于阴性患者(p=0.0006)。结论:我们的研究结果表明，SPINK2在AML的发展中起着重要作用。需要进一步的研究来评估SPINK2在t(8.21) AML患者中的表达，并研究阐明其在不同AML亚组中的预后价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in laboratory medicine

CiteScore

1.10

自引率

0.00%

发文量